Metabolic consequences of obesity and type 2 diabetes: Balancing genes and environment for personalized care.

Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Diabetes Research Group, Translational and Clinical Research Institute, Faculty of Clinical Medical Sciences, Newcastle University, 4(th) Floor William Leech Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK. Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. Electronic address: juleen.zierath@ki.se.

Cell. 2021;(6):1530-1544
Full text from:

Abstract

The prevalence of type 2 diabetes and obesity has risen dramatically for decades and is expected to rise further, secondary to the growing aging, sedentary population. The strain on global health care is projected to be colossal. This review explores the latest work and emerging ideas related to genetic and environmental factors influencing metabolism. Translational research and clinical applications, including the impact of the COVID-19 pandemic, are highlighted. Looking forward, strategies to personalize all aspects of prevention, management and care are necessary to improve health outcomes and reduce the impact of these metabolic diseases.

Methodological quality

Publication Type : Review

Metadata

MeSH terms : Precision Medicine